Biology Reference
In-Depth Information
xylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled admin-
istration. J Pharmacol Exp Ther 307:373-385
Lamontagne S, Meadows E, Luk P, Normandin D, Muise E, Boulet L, Pon DJ, Robichaud A,
Robertson GS, Metters KM, Nantel F (2001) Localization of phosphodiesterase-4 isoforms in
the medulla and nodose ganglion of the squirrel monkey. Brain Res 920:84-96
Landells LJ, Szilagy CM, Jones NA, Banner KH, Allen JM, Doherty A, O'Connor BJ, Spina D,
Page CP (2001) Identification and quantification of phosphodiesterase 4 subtypes in CD4 and
CD8 lymphocytes from healthy and asthmatic subjects. Br J Pharmacol 133:722-729
Leclerc O, Lagente V, Planquois JM, Berthelier C, Artola M, Eichholtz T, Bertrand CP, Schmidlin
F (2006) Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced
inflammation in mice. Eur Respir J 27:1102-1109
Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SL,
Conti M, Marks AR (2005) Phosphodiesterase 4D deficiency in the ryanodine-receptor com-
plex promotes heart failure and arrhythmias. Cell 123:25-35
Louw C, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbroker D, Bardin PG
(2007) Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after
allergen challenge. Respiration 74:411-417
Lu S, Liu N, Dass SB, Reiss TF, Knorr BA (2009) Randomized, placebo-controlled study of
a selective PDE4 inhibitor in the treatment of asthma. Respir Med 103:342-347
Ma R, Yang BY, Wu CY (2008) A selective phosphodiesterase 4 (PDE4) inhibitor Zl-n-91
suppresses IL-17 production by human memory Th17 cells. Int Immunopharmacol 8:1408-1417
Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M, Torphy TJ,
Barnette MS (1999) Suppression of human inflammatory cell function by subtype- selective
PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 128:
1393-1398
Martin-Chouly CA, Astier A, Jacob C, Pruniaux MP, Bertrand C, Lagente V (2004) Modulation of
matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase
inhibitors. Life Sci 75:823-840
Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G (2005) Roflumilast fully prevents
emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med
172:848-853
McCahill AC, Huston E, Li X, Houslay MD (2008) PDE4 associates with different scaffolding
proteins: modulating interactions as treatment for certain diseases. Handb Exp Pharmacol
(186); 125-166
McCluskie K, Klein U, Linnevers C, Ji YH, Yang A, Husfeld C, Thomas GR (2006) Phosphodi-
esterase type 4 inhibitors cause proinflammatory effects in vivo. J Pharmacol Exp Ther
319:468-476
Mehats C, Jin SL, Wahlstrom J, Law E, Umetsu DT, Conti M (2003) PDE4D plays a critical role in
the control of airway smooth muscle contraction. FASEB J 17:1831-1841
Millar JK, Mackie S, Clapcote SJ, Murdoch H, Pickard BS, Christie S, Muir WJ, Blackwood DH,
Roder JC, Houslay MD, Porteous DJ (2007) Disrupted in schizophrenia 1 and phosphodiester-
ase 4B: towards an understanding of psychiatric illness. J Physiol 584:401-405
Nazarian R, Weinberg JM (2009) AN-2728, a PDE4 inhibitor for the potential topical treatment of
psoriasis and atopic dermatitis. Curr Opin Investig Drugs 10:1236-1242
Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361:496-509
Noh AL, Yang M, Lee JM, Park H, Lee DS, Yim M (2009) Phosphodiesterase 3 and 4 negatively
regulate receptor activator of nuclear factor-kappaB ligand-mediated osteoclast formation by
prostaglandin E2. Biol Pharm Bull 32:1844-1848
Nyce JW, Metzger WJ (1997) DNA antisense therapy for asthma in an animal model. Nature
385:721-725
Nyska A, Herbert RA, Chan PC, Haseman JK, Hailey JR (1998) Theophylline-induced mesenteric
periarteritis in F344/N rats. Arch Toxicol 72:731-737
